{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:43:57Z","timestamp":1789533837117,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,9,14]],"date-time":"2017-09-14T00:00:00Z","timestamp":1505347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Several groups have proposed that genotypic determinants in <jats:italic>gag<\/jats:italic> and the <jats:italic>gp41<\/jats:italic> cytoplasmic domain (<jats:italic>gp41<\/jats:italic>-CD) reduce protease inhibitor (PI) susceptibility without PI-resistance mutations in protease. However, no <jats:italic>gag<\/jats:italic> and <jats:italic>gp41<\/jats:italic>-CD mutations definitively responsible for reduced PI susceptibility have been identified in individuals with virological failure (VF) while receiving a boosted PI (PI\/r)-containing regimen. To identify <jats:italic>gag<\/jats:italic> and <jats:italic>gp41<\/jats:italic> mutations under selective PI pressure, we sequenced <jats:italic>gag<\/jats:italic> and\/or <jats:italic>gp41<\/jats:italic> in 61 individuals with VF on a PI\/r (n\u2009=\u200940) or NNRTI (n\u2009=\u200920) containing regimen. We quantified nonsynonymous and synonymous changes in both genes and identified sites exhibiting signal for directional or diversifying selection. We also used published <jats:italic>gag<\/jats:italic> and <jats:italic>gp41<\/jats:italic> polymorphism data to highlight mutations displaying a high selection index, defined as changing from a conserved to an uncommon amino acid. Many amino acid mutations developed in <jats:italic>gag<\/jats:italic> and in <jats:italic>gp41-<\/jats:italic>CD in both the PI- and NNRTI-treated groups. However, in neither gene, were there discernable differences between the two groups in overall numbers of mutations, mutations displaying evidence of diversifying or directional selection, or mutations with a high selection index. If <jats:italic>gag<\/jats:italic> and\/or <jats:italic>gp41<\/jats:italic> encode PI-resistance mutations, they may not be confined to consistent mutations at a few sites.<\/jats:p>","DOI":"10.1038\/s41598-017-11893-8","type":"journal-article","created":{"date-parts":[[2017,9,11]],"date-time":"2017-09-11T10:13:15Z","timestamp":1505124795000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evolution of gag and gp41 in Patients Receiving Ritonavir-Boosted Protease Inhibitors"],"prefix":"10.1038","volume":"7","author":[{"given":"Justen","family":"Manasa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vici","family":"Varghese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergei L. Kosakovsky","family":"Pond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo-Yon","family":"Rhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2876-1552","authenticated-orcid":false,"given":"Philip L.","family":"Tzou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. Jeffrey","family":"Fessel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0000-3848","authenticated-orcid":false,"given":"Karen S.","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thorsteinn","family":"R\u00f6gnvaldsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Katzenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert W.","family":"Shafer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,14]]},"reference":[{"key":"11893_CR1","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/v2112509","volume":"2","author":"A Ali","year":"2010","unstructured":"Ali, A. et al. Molecular Basis for Drug Resistance in HIV-1 Protease. Viruses \n                           2, 2509\u20132535, https:\/\/doi.org\/10.3390\/v2112509 (2010).","journal-title":"Viruses"},{"key":"11893_CR2","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1093\/jac\/dkr569","volume":"67","author":"TJ Barber","year":"2012","unstructured":"Barber, T. J. et al. Frequency and patterns of protease gene resistance mutations in HIV-infected patients treated with lopinavir\/ritonavir as their first protease inhibitor. J Antimicrob Chemother \n                           67, 995\u20131000, https:\/\/doi.org\/10.1093\/jac\/dkr569 (2012).","journal-title":"J Antimicrob Chemother"},{"key":"11893_CR3","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1093\/jac\/dkt199","volume":"68","author":"DI Dolling","year":"2013","unstructured":"Dolling, D. I. et al. Low frequency of genotypic resistance in HIV-1-infected patients failing an atazanavir-containing regimen: a clinical cohort study. J Antimicrob Chemother \n                           68, 2339\u20132343, https:\/\/doi.org\/10.1093\/jac\/dkt199 (2013).","journal-title":"J Antimicrob Chemother"},{"key":"11893_CR4","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1097\/QAD.0b013e32832d7350","volume":"23","author":"AM Mills","year":"2009","unstructured":"Mills, A. M. et al. Once-daily darunavir\/ritonavir vs. lopinavir\/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS \n                           23, 1679\u20131688, https:\/\/doi.org\/10.1097\/QAD.0b013e32832d7350 (2009).","journal-title":"AIDS"},{"key":"11893_CR5","doi-asserted-by":"publisher","first-page":"3487","DOI":"10.1093\/jac\/dkw343","volume":"71","author":"K El Bouzidi","year":"2016","unstructured":"El Bouzidi, K. et al. HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK. J Antimicrob Chemother \n                           71, 3487\u20133494, https:\/\/doi.org\/10.1093\/jac\/dkw343 (2016).","journal-title":"J Antimicrob Chemother"},{"key":"11893_CR6","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1038\/nm.2892","volume":"18","author":"DI Rosenbloom","year":"2012","unstructured":"Rosenbloom, D. I., Hill, A. L., Rabi, S. A., Siliciano, R. F. & Nowak, M. A. Antiretroviral dynamics determines HIV evolution and predicts therapy outcome. Nat Med \n                           18, 1378\u20131385, https:\/\/doi.org\/10.1038\/nm.2892 (2012).","journal-title":"Nat Med"},{"key":"11893_CR7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050307","volume":"7","author":"AU Scherrer","year":"2012","unstructured":"Scherrer, A. U. et al. Long-lasting protection of activity of nucleoside reverse transcriptase inhibitors and protease inhibitors (PIs) by boosted PI containing regimens. PLoS One \n                           7, e50307, https:\/\/doi.org\/10.1371\/journal.pone.0050307 (2012).","journal-title":"PLoS One"},{"key":"11893_CR8","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1093\/infdis\/jis613","volume":"206","author":"K Mollan","year":"2012","unstructured":"Mollan, K. et al. HIV-1 amino acid changes among participants with virologic failure: associations with first-line efavirenz or atazanavir plus ritonavir and disease status. J Infect Dis \n                           206, 1920\u20131930, https:\/\/doi.org\/10.1093\/infdis\/jis613 (2012).","journal-title":"J Infect Dis"},{"key":"11893_CR9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1086\/380509","volume":"189","author":"DJ Kempf","year":"2004","unstructured":"Kempf, D. J. et al. Incidence of resistance in a double-blind study comparing lopinavir\/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis \n                           189, 51\u201360, https:\/\/doi.org\/10.1086\/380509 (2004).","journal-title":"J Infect Dis"},{"key":"11893_CR10","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1093\/cid\/ciu367","volume":"59","author":"Y Zheng","year":"2014","unstructured":"Zheng, Y. et al. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens. Clin Infect Dis \n                           59, 888\u2013896, https:\/\/doi.org\/10.1093\/cid\/ciu367 (2014).","journal-title":"Clin Infect Dis"},{"key":"11893_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0148924","volume":"11","author":"LF Lopez-Cortes","year":"2016","unstructured":"Lopez-Cortes, L. F. et al. Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens. PLoS One \n                           11, e0148924, https:\/\/doi.org\/10.1371\/journal.pone.0148924 (2016).","journal-title":"PLoS One"},{"key":"11893_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-9-63","volume":"9","author":"A Fun","year":"2012","unstructured":"Fun, A., Wensing, A. M., Verheyen, J. & Nijhuis, M. Human Immunodeficiency Virus Gag and protease: partners in resistance. Retrovirology \n                           9, 63, https:\/\/doi.org\/10.1186\/1742-4690-9-63 (2012).","journal-title":"Retrovirology"},{"key":"11893_CR13","doi-asserted-by":"publisher","first-page":"3848","DOI":"10.1172\/JCI67399","volume":"123","author":"SA Rabi","year":"2013","unstructured":"Rabi, S. A. et al. Multi-step inhibition explains HIV-1 protease inhibitor pharmacodynamics and resistance. J Clin Invest \n                           123, 3848\u20133860, https:\/\/doi.org\/10.1172\/JCI67399 (2013).","journal-title":"J Clin Invest"},{"key":"11893_CR14","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1128\/AAC.44.4.920-928.2000","volume":"44","author":"CJ Petropoulos","year":"2000","unstructured":"Petropoulos, C. J. et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother \n                           44, 920\u2013928 (2000).","journal-title":"Antimicrob Agents Chemother"},{"key":"11893_CR15","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1093\/bioinformatics\/bti079","volume":"21","author":"SL Pond","year":"2005","unstructured":"Pond, S. L., Frost, S. D. & Muse, S. V. HyPhy: hypothesis testing using phylogenies. Bioinformatics \n                           21, 676\u2013679, https:\/\/doi.org\/10.1093\/bioinformatics\/bti079 (2005).","journal-title":"Bioinformatics"},{"key":"11893_CR16","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1093\/molbev\/msv035","volume":"32","author":"B Murrell","year":"2015","unstructured":"Murrell, B. et al. Gene-wide identification of episodic selection. Mol Biol Evol \n                           32, 1365\u20131371, https:\/\/doi.org\/10.1093\/molbev\/msv035 (2015).","journal-title":"Mol Biol Evol"},{"key":"11893_CR17","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1093\/molbev\/msi105","volume":"22","author":"SL Kosakovsky Pond","year":"2005","unstructured":"Kosakovsky Pond, S. L. & Frost, S. D. Not so different after all: a comparison of methods for detecting amino acid sites under selection. Mol Biol Evol \n                           22, 1208\u20131222, https:\/\/doi.org\/10.1093\/molbev\/msi105 (2005).","journal-title":"Mol Biol Evol"},{"key":"11893_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1002507","volume":"8","author":"B Murrell","year":"2012","unstructured":"Murrell, B. et al. Modeling HIV-1 drug resistance as episodic directional selection. PLoS Comput Biol \n                           8, e1002507, https:\/\/doi.org\/10.1371\/journal.pcbi.1002507 (2012).","journal-title":"PLoS Comput Biol"},{"key":"11893_CR19","unstructured":"LANL. CTL\/CD8+ epitope summary files (last updated June 16, 2017). http:\/\/www.hiv.lanl.gov\/content\/immunology (2017)."},{"key":"11893_CR20","doi-asserted-by":"publisher","first-page":"3429","DOI":"10.1128\/JVI.78.7.3429-3435.2004","volume":"78","author":"DJ Wyma","year":"2004","unstructured":"Wyma, D. J. et al. Coupling of human immunodeficiency virus type 1 fusion to virion maturation: a novel role of the gp41 cytoplasmic tail. J Virol \n                           78, 3429\u20133435 (2004).","journal-title":"J Virol"},{"key":"11893_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1128\/JVI.78.2.1026-1031.2004","volume":"78","author":"T Murakami","year":"2004","unstructured":"Murakami, T., Ablan, S., Freed, E. O. & Tanaka, Y. Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol \n                           78, 1026\u20131031 (2004).","journal-title":"J Virol"},{"key":"11893_CR22","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1093\/bioinformatics\/btu810","volume":"31","author":"T Rognvaldsson","year":"2015","unstructured":"Rognvaldsson, T., You, L. & Garwicz, D. State of the art prediction of HIV-1 protease cleavage sites. Bioinformatics \n                           31, 1204\u20131210, https:\/\/doi.org\/10.1093\/bioinformatics\/btu810 (2015).","journal-title":"Bioinformatics"},{"key":"11893_CR23","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1128\/JVI.01879-10","volume":"85","author":"H Crawford","year":"2011","unstructured":"Crawford, H. et al. The hypervariable HIV-1 capsid protein residues comprise HLA-driven CD8+ T-cell escape mutations and covarying HLA-independent polymorphisms. J Virol \n                           85, 1384\u20131390, https:\/\/doi.org\/10.1128\/JVI.01879-10 (2011).","journal-title":"J Virol"},{"key":"11893_CR24","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/jvi.70.6.3763-3769.1996","volume":"70","author":"L Doyon","year":"1996","unstructured":"Doyon, L. et al. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors. J Virol \n                           70, 3763\u20133769 (1996).","journal-title":"J Virol"},{"key":"11893_CR25","doi-asserted-by":"crossref","first-page":"6662","DOI":"10.1128\/jvi.71.9.6662-6670.1997","volume":"71","author":"YM Zhang","year":"1997","unstructured":"Zhang, Y. M. et al. Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites. J Virol \n                           71, 6662\u20136670 (1997).","journal-title":"J Virol"},{"key":"11893_CR26","doi-asserted-by":"publisher","first-page":"7398","DOI":"10.1128\/JVI.76.15.7398-7406.2002","volume":"76","author":"MF Maguire","year":"2002","unstructured":"Maguire, M. F. et al. Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro. J Virol \n                           76, 7398\u20137406 (2002).","journal-title":"J Virol"},{"key":"11893_CR27","doi-asserted-by":"publisher","first-page":"12446","DOI":"10.1128\/JVI.78.22.12446-12454.2004","volume":"78","author":"M Prabu-Jeyabalan","year":"2004","unstructured":"Prabu-Jeyabalan, M., Nalivaika, E. A., King, N. M. & Schiffer, C. A. Structural basis for coevolution of a human immunodeficiency virus type 1 nucleocapsid-p1 cleavage site with a V82A drug-resistant mutation in viral protease. J Virol \n                           78, 12446\u201312454, https:\/\/doi.org\/10.1128\/JVI.78.22.12446-12454.2004 (2004).","journal-title":"J Virol"},{"key":"11893_CR28","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1128\/JVI.75.2.589-594.2001","volume":"75","author":"HC Cote","year":"2001","unstructured":"Cote, H. C., Brumme, Z. L. & Harrigan, P. R. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and\/or saquinavir. J Virol \n                           75, 589\u2013594, https:\/\/doi.org\/10.1128\/JVI.75.2.589-594.2001 (2001).","journal-title":"J Virol"},{"key":"11893_CR29","doi-asserted-by":"crossref","first-page":"7632","DOI":"10.1128\/JVI.72.9.7632-7637.1998","volume":"72","author":"F Mammano","year":"1998","unstructured":"Mammano, F., Petit, C. & Clavel, F. Resistance-associated loss of viral fitness in human immunodeficiency virus type 1: phenotypic analysis of protease and gag coevolution in protease inhibitor-treated patients. J Virol \n                           72, 7632\u20137637 (1998).","journal-title":"J Virol"},{"key":"11893_CR30","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1074\/jbc.M108005200","volume":"277","author":"H Gatanaga","year":"2002","unstructured":"Gatanaga, H. et al. Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors. J Biol Chem \n                           277, 5952\u20135961, https:\/\/doi.org\/10.1074\/jbc.M108005200 (2002).","journal-title":"J Biol Chem"},{"key":"11893_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0040036","volume":"4","author":"M Nijhuis","year":"2007","unstructured":"Nijhuis, M. et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med \n                           4, e36, https:\/\/doi.org\/10.1371\/journal.pmed.0040036 (2007).","journal-title":"PLoS Med"},{"key":"11893_CR32","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1128\/JVI.01640-15","volume":"90","author":"AN Martins","year":"2015","unstructured":"Martins, A. N. et al. Elucidation of the Molecular Mechanism Driving Duplication of the HIV-1 PTAP Late Domain. J Virol \n                           90, 768\u2013779, https:\/\/doi.org\/10.1128\/JVI.01640-15 (2015).","journal-title":"J Virol"},{"key":"11893_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-016-0298-1","volume":"13","author":"SM Watanabe","year":"2016","unstructured":"Watanabe, S. M. et al. The HIV-1 late domain-2 S40A polymorphism in antiretroviral (or ART)-exposed individuals influences protease inhibitor susceptibility. Retrovirology \n                           13, 64, https:\/\/doi.org\/10.1186\/s12977-016-0298-1 (2016).","journal-title":"Retrovirology"},{"key":"11893_CR34","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-014-0079-7","volume":"11","author":"G Li","year":"2014","unstructured":"Li, G. et al. HIV-1 Gag C-terminal amino acid substitutions emerging under selective pressure of protease inhibitors in patient populations infected with different HIV-1 subtypes. Retrovirology \n                           11, 79, https:\/\/doi.org\/10.1186\/s12977-014-0079-7 (2014).","journal-title":"Retrovirology"},{"key":"11893_CR35","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1097\/QAD.0b013e3283398216","volume":"24","author":"RK Gupta","year":"2010","unstructured":"Gupta, R. K. et al. Full-length HIV-1 Gag determines protease inhibitor susceptibility within in vitro assays. AIDS \n                           24, 1651\u20131655 (2010).","journal-title":"AIDS"},{"key":"11893_CR36","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1097\/QAI.0b013e3181b4b18c","volume":"52","author":"P Jinnopat","year":"2009","unstructured":"Jinnopat, P. et al. Impact of amino acid variations in Gag and protease of HIV type 1 CRF01_AE strains on drug susceptibility of virus to protease inhibitors. J Acquir Immune Defic Syndr \n                           52, 320\u2013328, https:\/\/doi.org\/10.1097\/QAI.0b013e3181b4b18c (2009).","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11893_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1099\/vir.0.055624-0","volume":"95","author":"KA Sutherland","year":"2014","unstructured":"Sutherland, K. A., Mbisa, J. L., Cane, P. A., Pillay, D. & Parry, C. M. Contribution of Gag and protease to variation in susceptibility to protease inhibitors between different strains of subtype B human immunodeficiency virus type 1. J Gen Virol \n                           95, 190\u2013200, https:\/\/doi.org\/10.1099\/vir.0.055624-0 (2014).","journal-title":"J Gen Virol"},{"key":"11893_CR38","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1093\/jac\/dku296","volume":"69","author":"KA Sutherland","year":"2014","unstructured":"Sutherland, K. A. et al. Phenotypic characterization of virological failure following lopinavir\/ritonavir monotherapy using full-length Gag-protease genes. J Antimicrob Chemother \n                           69, 3340\u20133348, https:\/\/doi.org\/10.1093\/jac\/dku296 (2014).","journal-title":"J Antimicrob Chemother"},{"key":"11893_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-03260-4","volume":"7","author":"FM Codoner","year":"2017","unstructured":"Codoner, F. M. et al. Gag-protease coevolution analyses define novel structural surfaces in the HIV-1 matrix and capsid involved in resistance to Protease Inhibitors. Sci Rep \n                           7, 3717, https:\/\/doi.org\/10.1038\/s41598-017-03260-4 (2017).","journal-title":"Sci Rep"},{"key":"11893_CR40","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1089\/aid.2015.0138","volume":"31","author":"KA Sutherland","year":"2015","unstructured":"Sutherland, K. A. et al. Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa. AIDS Res Hum Retroviruses \n                           31, 1032\u20131037, https:\/\/doi.org\/10.1089\/aid.2015.0138 (2015).","journal-title":"AIDS Res Hum Retroviruses"},{"key":"11893_CR41","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/82_2015_438","volume":"389","author":"M Potempa","year":"2015","unstructured":"Potempa, M., Lee, S. K., Wolfenden, R. & Swanstrom, R. The triple threat of HIV-1 protease inhibitors. Curr Top Microbiol Immunol \n                           389, 203\u2013241, https:\/\/doi.org\/10.1007\/82_2015_438 (2015).","journal-title":"Curr Top Microbiol Immunol"},{"key":"11893_CR42","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1128\/AAC.05549-11","volume":"56","author":"GJ Henderson","year":"2012","unstructured":"Henderson, G. J. et al. Interplay between single resistance-associated mutations in the HIV-1 protease and viral infectivity, protease activity, and inhibitor sensitivity. Antimicrob Agents Chemother \n                           56, 623\u2013633, https:\/\/doi.org\/10.1128\/AAC.05549-11 (2012).","journal-title":"Antimicrob Agents Chemother"},{"key":"11893_CR43","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/molbev\/msm021","volume":"24","author":"C Seoighe","year":"2007","unstructured":"Seoighe, C. et al. A model of directional selection applied to the evolution of drug resistance in HIV-1. Mol Biol Evol \n                           24, 1025\u20131031, https:\/\/doi.org\/10.1093\/molbev\/msm021 (2007).","journal-title":"Mol Biol Evol"},{"key":"11893_CR44","doi-asserted-by":"publisher","first-page":"12456","DOI":"10.1073\/pnas.1615342113","volume":"113","author":"L Deshmukh","year":"2016","unstructured":"Deshmukh, L., Louis, J. M., Ghirlando, R. & Clore, G. M. Transient HIV-1 Gag-protease interactions revealed by paramagnetic NMR suggest origins of compensatory drug resistance mutations. Proc Natl Acad Sci USA \n                           113, 12456\u201312461, https:\/\/doi.org\/10.1073\/pnas.1615342113 (2016).","journal-title":"Proc Natl Acad Sci USA"},{"key":"11893_CR45","doi-asserted-by":"publisher","unstructured":"Kletenkov, K. et al. Role of Gag mutations in PI resistance in the Swiss HIV cohort study: bystanders or contributors? J Antimicrob Chemother, doi:https:\/\/doi.org\/10.1093\/jac\/dkw493 (2016).","DOI":"10.1093\/jac\/dkw493"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11893-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11893-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T10:49:49Z","timestamp":1671792589000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-11893-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["11893"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-11893-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,14]]},"assertion":[{"value":"22 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"R.W.S. has received research funding from Gilead Sciences, Merck, and Bristol Myers Squibb and has consulted for ViiV and Abbott Diagnostics.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"11559"}}